Articles tagged "Post-transplant malignancy"

2016 American Transplant Congress
An Epidemiological Update of Non-Melanoma Skin Cancer in Immunosuppressed Organ Transplant Recipients with Skin of Color.
C. Shaver, C. Cusack, C. Chung.
Dermatology, Drexel University College of Medicine, Philadelphia, PA.
Introduction:It is predicted by the US census that by year 2050, minorities will become the majority US population. We know skin cancer in patients with…
2016 American Transplant Congress
Thorough Pre-Transplant Evaluation and Appropriate Case Selection Is the Mainstay for Better Survival in Recipients with Malignancy.
W. Yin.^1,2
¹Surgery, School of Medicine, Tzu Chi University, Hualien, Taiwan; ²Surgery, Dalin Tzu Chi General Hospital, Chia-I, Taiwan.
IntroductionMalignancy has become one of the three major causes of death after transplantation in the past decade and is thus increasingly important in all organ…
2016 American Transplant Congress
Prostate Cancer Characteristics and Outcome in Renal Transplant Recipients: Results from a Contemporary Monocentric Study.
C. Pettenati,¹ A.-S. Jannot,² V. Verkarre,³ S. Hurel,¹ H. Kreis,⁴ M. Housset,⁵ C. Legendre,⁴ A. Méjean,¹ M.-O. Timsit.¹
¹Department of Urology and Transplant surgery, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Descartes, Paris, France; ²Department of Statistics, Computing and Public Health, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Descartes, Paris, France; ³Department of Pathology, Hôpital Necker, AP-HP, Université Paris Descartes, Paris, France; ⁴Department of Nephrology and Transplantation, Hôpital Necker, AP-HP, Université Paris Descartes, Paris, France; ⁵Department of Onco-Radiotherapy, Hôpital Necker, AP-HP, Université Paris Descartes, Paris, France.
Objective To analyze prostate cancer characteristics in a contemporary monocentric renal transplant recipients (RTR) population and to compare oncological outcome after radical prostatectomy (RP) with…
2015 American Transplant Congress
Detecting Bowel Cancer in Pre-Dialysis, Dialysis Patients and Kidney Transplant Recipients – The DETECT Study
G. Wong, J. Chapman, J. Craig.
University of Sydney, Sydney, NSW, Australia.
Background: Colorectal cancer (CRC) is the third most common solid organ cancer in people living with kidney disease, and has a very poor prognosis, with…
2015 American Transplant Congress
Deficiency of Naturally Occurring Anti-Angiogenic Antibodies Associate With the Development of Metastatic Cancer Post Renal Transplantation and Patient Death
R. Carroll,¹ A. Phillippe,² R. Catar,² H. Heidecke,² D. Dragun.²
¹Central Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, SA, Australia; ²Centre for Cardiovascular Research, Charite Hospital, Berlin, Germany.
We assessed the presence of naturally occurring blocking antibodies to mediators of vascularisation and metastasis in Kidney Transplant Recipients (KTR) with metastatic cancer (n=11), non…
2015 American Transplant Congress
Elevated Cancer Risk Among US Pediatric Solid Organ Transplant Recipients
E. Yanik,¹ J. Smith,² M. Shiels,¹ C. Clarke,³ C. Lynch,⁴ A. Kahn,⁵ L. Koch,⁶ K. Pawlish,⁷ E. Engels.¹
¹Natl. Cancer Inst., Bethesda, MD; ²Seattle Children's Hosp., Seattle, WA; ³Cancer Prev. Inst. of CA, Fremont, CA; ⁴U. of Iowa, Iowa City, IA; ⁵NY St. Cancer Reg., Albany, NY; ⁶IL St. Cancer Reg., Springfield, IL; ⁷NJ St. Cancer Reg., Trenton, NJ.
Among pediatric transplant recipients, the effects of transplantation and immunosuppression on cancer risk may be unique from those observed in the adult transplant population. No…
2015 American Transplant Congress
Pre-Transplant Desensitization Protocol and Cancer Risk in Kidney Transplantation
I. Revuelta,^1,2,3 R. Ferreira,¹ C. Canha,¹ P. Piselli,⁴ D. Verdirosi,⁴ V. Tubita,² E. De Sousa,¹ F. Diekmann,^1,2,3 M. Lozano,^2,5 J. Cid,⁵ E. Palou,⁶ J. Martorell,⁶ A. Alcaraz,⁷ D. Serraino,⁸ F. Oppenheimer,^1,2,3 J. Campistol.^1,2,3
¹Renal Transplant Unit, Department of Nephrology and Kidney Transplant, Hospital Clinic, Barcelona, Spain; ²IDIBAPS, Barcelona, Spain; ³REDinREN. Carlos III Royal Institute. Ministry of Health, Madrid, Spain; ⁴Dipartamento di Epidemiologia e Ricerca Pre-Clinica, INMI “L. Spallanzani” IRCCC, Rome, Italy; ⁵Hemotherapy and Hemostasis, Hospital Clinic, Barcelona, Spain; ⁶Department of Immunology, Hospital Clinic, Barcelona, Spain; ⁷Department of Urology, Hospital Clinic, Barcelona, Spain; ⁸IRCCS Centro di Riferimento Oncologico, Aviano, Italy.
Introduction: Desensitization (DS) in kidney transplant is a current therapy for all cause of incompatible living donor kidney transplants (LDKT). The impact in cancer risk…
2015 American Transplant Congress
The Onset of Post-Transplant Malignancies Is Related to a Change in Gene Expression Profiles in Peripheral Blood Mononuclear Cells
G. Stallone,¹ R. Federica,¹ P. Pontrelli,² M. Accetturo,² A. Oranger,² M. Gigante,² G. Castellano,² A. Schena,² M. Fiorentino,² B. Infante,¹ L. Gesualdo,² G. Grandaliano.¹
¹Dept.of Surgical and Medical Sciences, Nephrology Unit, University of Foggia, Foggia, Italy; ²Dept. of Emergency and Organ Transplantation, Nephrology Unit, University of Bari, Bari, Italy.
Malignancies are the third leading cause of death in renal transplant recipients and their incidence is increasing. Although the role of the immune system in…
2015 American Transplant Congress
24 Month Post Transplantation Follow Up of the Certitem Trial
E. Rondeau,¹ E. Cassuto,² V. Vuiblet,³ C. Legendre,⁴ P. Merville,⁵ Y. Le Meur,⁶ B. Moulin,⁷ P. Westeel,⁸ B. Hurault De Ligny,⁹ A. Lécuyer,¹⁰ M. Tindel,¹¹ N. Kamar.¹²
¹Hôpital Tenon, Paris, France; ²Hôpital Pasteur, Nice, France; ³Hôpital Maison Blanche, Reims, France; ⁴Hôpital Necker, Paris, France; ⁵Hôpital Pellegrin, Bordeaux, France; ⁶Hôpital La Cavale Blanche, Brest, France; ⁷Nouvel Hôpital Civil, Strasbourg, France; ⁸Hôpital Sud, Amiens, France; ⁹CHU, Caen, France; ¹⁰Novartis Pharma S.A.S, Rueil-Malmaison, France; ¹¹Keyrus Biopharma, Levallois-Perret, France; ¹²Hôpital Rangueil, Toulouse, France.
Background: CERTITEM has evaluated the effect of everolimus/calcineurin inhibitors free (CNI free) on fibrosis progression and results have been reported at 12 months (M12). Data…
2015 American Transplant Congress
Verification of OPTN Hepatocellular Carcinoma Recurrence Data
J. George,¹ K. Eddinger,¹ D. Goldberg,² M. Levine,³ P. Abt.³
¹Perelman School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA; ²Division of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, PA; ³Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA.
PURPOSE: OPTN data on HCC recurrence is increasingly utilized for a variety of studies; however, the accuracy of this data has not been examined. We…